{
    "Trade/Device Name(s)": [
        "FINDER G6PD Test"
    ],
    "Submitter Information": "Baebies, Inc.",
    "510(k) Number": "K201049",
    "Predicate Device Reference 510(k) Number(s)": [
        "K024006"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JBF"
    ],
    "Summary Letter Date": "September 14, 2022",
    "Summary Letter Received Date": "June 17, 2022",
    "Submission Date": "September 12, 2022",
    "Regulation Number(s)": [
        "21 CFR 864.7360"
    ],
    "Regulation Name(s)": [
        "Erythrocytic Glucose-6-Phosphate Dehydrogenase Assay"
    ],
    "Analyte Class(es)": [
        "hematology"
    ],
    "Analyte(s)": [
        "Glucose-6-phosphate dehydrogenase (G6PD)"
    ],
    "Specimen Type(s)": [
        "Venous whole blood"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "FINDER Instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Electrowetting-based digital microfluidics",
        "NADPH kinetic fluorometric method"
    ],
    "Methodologies": [
        "Semi-quantitative enzyme activity measurement"
    ],
    "Submission Type(s)": [
        "Test",
        "Cartridge",
        "Instrument",
        "Accessory",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for Baebies FINDER G6PD Test measuring glucose-6-phosphate dehydrogenase activity in whole blood using a microfluidics cartridge and dedicated instrument",
    "Indications for Use Summary": "Semi-quantitative measurement of glucose-6-phosphate dehydrogenase in venous whole blood collected in lithium heparin tubes for identification of G6PD deficient samples, intended for use with the FINDER Instrument in point-of-care or clinical laboratory settings",
    "fda_folder": "Hematology"
}